2014;515:568–71. 71. S tagg J and Allard B. Immunotherapeutic approaches in triplenegative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol. 2013; 5(3) 169 –181. DOI: 10.1177/1758834012475152 72. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death l igand-1 expression in non-small cell lung cancer. Lab Invest. 2014; 94:107–16. 73. Hamid O, Robert C, Daud A, Hodi FS, et al. Safety and tumor responses with lambrolizumab (anti- PD-1) in melanoma. N Engl J Med.